Home Cart Sign in  
Chemical Structure| 210110-90-0 Chemical Structure| 210110-90-0

Structure of Miglustat HCl
CAS No.: 210110-90-0

Chemical Structure| 210110-90-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Miglustat HCl is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).

Synonyms: OGT 918 hydrochloride; N-Butyldeoxynojirimycin hydrochloride; NB-DNJ

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Miglustat HCl

CAS No. :210110-90-0
Formula : C10H22ClNO4
M.W : 255.74
SMILES Code : O[C@@H]1[C@@H](CO)N(CCCC)C[C@H](O)[C@H]1O.[H]Cl
Synonyms :
OGT 918 hydrochloride; N-Butyldeoxynojirimycin hydrochloride; NB-DNJ
MDL No. :MFCD00269940
InChI Key :QPAFAUYWVZMWPR-ZSOUGHPYSA-N
Pubchem ID :6603107

Safety of Miglustat HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H361
Precautionary Statements:P501-P202-P201-P280-P308+P313-P405

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01760564 Niemann-Pick Disease Type C PHASE3 COMPLETED 2025-12-10 National Taiwan University Hos... More >>pital, Taipei, Taiwan Less <<
NCT03910621 Niemann-Pick Disease, Type C PHASE4 COMPLETED 2022-03-25 Peking University first Hospit... More >>al, Beijing, 100034, China|Xin Hua Hospital, Shanghai Jiao Tong University, Shanghai, 200092, China Less <<
NCT00319046 Gaucher Disease Type 1 PHASE3 COMPLETED 2010-07-01 -
NCT03822013 GM2 Gangliosidosis|Supportive ... More >>Care Less << PHASE3 RECRUITING 2024-12-30 Kashan University Of Medical S... More >>ciences, Kashan, Isfahan, Iran, Islamic Republic of|Mashhad University Of Medical Sciences, Mashhad, Khorasan, Iran, Islamic Republic of|Tehran University Of Medical Sciences, Tehran, Iran, Islamic Republic of Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.91mL

0.78mL

0.39mL

19.55mL

3.91mL

1.96mL

39.10mL

7.82mL

3.91mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories